Table 3.

Summary of Finerenone in head-to-head randomized controlled trials.

Study (Year)	Design	Population	Intervention vs. Control	Primary Outcome	Effect Size
Zhang et al. (2022) [36]	Network meta-analysis	-	Finerenone vs. SGLT2i and GLP-1 agonist	Cardiorenal outcomes	SGLT2i significantly decreased the risk of renal events and HHF in comparison. All three were comparable in MACE, ACD, and CVD.
ARTS part A and B (2013) [26]	RCT	HFrEF and CKD	Finerenone 2.5–10 mg once daily vs. placebo (part A) and spironolactone (part B)	Change in potassium	Finerenone 10 mg once daily and 5 mg twice daily led to higher mean increases in serum potassium than the placebo but lower levels than spironolactone
ARTS-HF (2016) [27]	RCT	HFrEF and T2D and/or CKD	Finerenone 2.5–15 mg once daily vs. eplerenone 25–50 mg once daily	>30% decline in NT-proBNP	There was no difference in the NT-proBNP decline in Finerenone versus eplerenone

RCT = randomized controlled trial; HFrEF = heart failure with reduced ejection fraction; CKD = chronic kidney disease; T2D = type 2 diabetes; SGLT2i = sodium–glucose cotransporter-2 inhibitor; GLP-1 agonist = glucagon-like peptide-1 receptor agonist; NT-proBNP = N-terminal prohormone of brain natriuretic peptide; HHF = hospitalization for heart failure; MACE = major adverse cardiovascular events; ACD = all-cause death; CVD = cardiovascular death.